Results 41 to 50 of about 8,274 (166)
Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma.
Yasuhiko Koga +7 more
doaj +1 more source
Summary of pregnancy management in CTD‐ILD across preconception, antenatal, and postpartum phases, emphasizing risk stratification and multidisciplinary care. 6MWT, 6‐min walk test; CTD‐ILD: connective tissue disease‐interstitial lung disease; DLCO, diffusion capacity of the lung for carbon monoxide; FVC, forced vital capacity; MDT, multidisciplinary ...
Khaled Aldhuaina +3 more
wiley +1 more source
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) impacts patients' concentration, ability to work, and overall quality of life. Current treatment options include topical and oral medications, and surgery. Recent evidence supports the efficacy of biologics in improving symptoms and quality of life.
Baharudin Abdullah +19 more
wiley +1 more source
Effectiveness of low-dose mepolizumab in refractory eosinophilic granulomatosis with polyangiitis: systemic steroid use and remission [PDF]
Background/Aims This study investigated the clinical efficacy of low-dose mepolizumab (100 mg) in controlling severe eosinophilic asthma, aiming to induce eosinophilic granulomatosis with polyangiitis (EGPA) remission and reduce systemic steroid usage ...
Mi-Ae Kim +6 more
doaj +1 more source
Both Full and Limited FESS result in clinically meaningful relief of disease‐specific HRQoL and nasal breathing, effectively improving nasal symptoms and sleep disturbance in CRSwNP patients. Clinically meaningful difference in decrease of SNOT‐22 scores between the groups was not found at 12‐ and 24–month follow‐up.
P. Virkkula +10 more
wiley +1 more source
Clinical manifestations of study patients with EGPA.
EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss); BVAS: Birmingham Vasculitis Activity Score; BVAS/WG: BVAS for Wegener’s Granulomatosis; n (%), number and percentage of patients (out of those with known outcome) with manifestation ...
David Cuthbertson (188652) +14 more
core +1 more source
Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by eosinophilic granulomatous vasculitis. Typical symptoms include late-onset bronchial asthma and blood and tissue eosinophilia.
Agata Sebastian, Joanna Kosałka-Węgiel
doaj +1 more source
Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz +22 more
wiley +1 more source
ObjectiveThe relationship between leukotriene receptor antagonists (LTRAs) usage and the subsequent occurrence of eosinophilic granulomatosis with polyangiitis (EGPA) remained highly polarizing and controversial in previous studies.
Cuilv Liang, Pingping Zhuo, Yin Zhang
doaj +1 more source
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic necrotising vasculitis characterised by tissue and blood hypereosinophilia.
Reinhard E Voll +7 more
doaj +1 more source

